Opinion/decision on a Paediatric investigation plan (PIP): Imbruvica, Ibrutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immunology-Rheumatology-Transplantation, PIP number: P/0295/2023

Opinion/decision on a Paediatric investigation plan (PIP): Sivextro, tedizolid phosphate, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0340/2023

Opinion/decision on a Paediatric investigation plan (PIP): Mysimba, bupropion hydrochloride,naltrexone hydrochloride, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Other, PIP number: P/0294/2023

Opinion/decision on a Paediatric investigation plan (PIP): Ocaliva, Obeticholic acid, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastroentology-Hepatology, PIP number: P/0287/2023

Opinion/decision on a Paediatric investigation plan (PIP): Cometriq, cabozantinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0309/2023

Opinion/decision on a Paediatric investigation plan (PIP): Eliquis, Apixaban, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiovascular diseases, PIP number: P/0338/2023

Human medicines European public assessment report (EPAR): Celsentri, maraviroc, Date of authorisation: 18/09/2007, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Date of authorisation: 16/12/2019, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Signifor, pasireotide, Date of authorisation: 24/04/2012, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): Axitinib Accord, axitinib, Date of authorisation: 19/09/2024, Status: Authorised